Teva to pay $27.6m to settle fraud charges
Chairman Shimon Eckhouse: Start-ups can operate faster than a company like us. Syneron is a young company, but they are a lot younger than we are.
Aesthetic laser device developer Syneron Medical Ltd. (Nasdaq: ELOS) has acquired privately-held Pharos Life Corporation, a manufacturer of home-use light therapy for aesthetic procedures, for about $15.8 million. The figure consists of $2.5 million in net debt that Syneron will assume, plus up to $13.25 million in milestone payments in 2013.
"We will continue to invest in start-ups. Start-ups can operate faster than a company like us. Syneron is a young company, but they are a lot younger than we are," Syneron founder and chairman Dr. Shimon Eckhouse told "Globes" two months ago.
Syneron has $212.4 million in cash, so there will be no problem financing the acquisition. Phasor Life markets its products directly to consumers through premium retailers under the Tända brand name. Products include skincare and wellness solutions for both the home-use and professional markets.
Pharos will continue operating as a wholly owned subsidiary of Syneron and the Tända business will be integrated into Syneron's consumer home-use initiatives.
The Pharos Life acquisition points to two strategies that Syneron is pursuing since the credit crunch. One is strengthening its presence in the home-use devices market, as opposed to its products for doctors, clinics, and spas. Syneron first entered the home-use market through a collaboration with Procter & Gamble (NYSE: PG), but little has come of it.
Syneron's second strategy is investing in other companies' technologies, rather than relying solely on its R&D department. In this way, the company hopes to increase its basket of products. With its large cash reserves and the large number of companies in the industry, Syeneron has little problem in making acquisitions of technologies and companies.
Pharos Life was founded seven years ago. Given the price tag for the company, it apparently has only a few million dollars in revenue.
Syneron's share price rose 2.4% yesterday to $10.60, giving a market cap of $365 million.
Published by Globes [online], Israel business news - www.globes-online.com - on December 9, 2010
© Copyright of Globes Publisher Itonut (1983) Ltd. 2010
You comment was recieved and soon will be published.
Load more comments
The company does not admit to charges of paying a psychiatrist to prescribe Clozapine.
Dermatology co Foamix mulls Nasdaq IPO
The developer of foam-based dermatology treatments is seeking underwriters.
Can-Fite Biopharma raises $5m
The proceeds will finance clinical trials for psoriasis, glaucoma, and liver cancer treatments.
Teva switching Copaxone users to new dosage
"Bloomberg": Teva has switched 8.7% of Copaxone's multiple sclerosis patients to the 40 milligram dosage.
Immune Pharmaceuticals raises $11.7m on Nasdaq
The money raised will fund a Phase II trial of ulcerative colitis drug bertilmumab.
XTL Biopharma files to raise $40m on Nasdaq
XTL plans to initiate a large Phase IIb clinical trial for the treatment of Lupus.
Teva launches generic cancer drug
Brand Xeloda, made by Genentech, had $754 million in US sales in 2013.
Yelin Lapidot takes stake in Brainsway
Brainsway raised NIS 41 million in the private placement.
Barclays upgrades Teva
Barclays raised its recommendation to "Overweight" and its target price to $65.
BiolineRX raises $24m in Nasdaq offering
Three months ago, the company announced promising preliminary clinical trial results.
Teva VP Ika Abravanel resigns
Abravanel's is the first senior departure from Teva since Erez Vigodman became CEO.
FDA approves Pluristem cell production facility
Pluristem's Haifa plant can produce 150,000 doses of PLX cells annually.
Desheh: Splitting Teva will not create value
Teva CFO Eyal Desheh says Teva's tight integration means that a split makes no sense.
InsuLine expanding in Europe
24Care will distribute the company's InsuPad product in the Netherlands and Belgium.
Teva launches generic breast cancer, osteoporosis drug
Teva has 180 days of marketing exclusivity for generic Evista, which had 2013 US sales of $824 million.
BiolineRX raising $21m in Nasdaq secondary offering
The company will use the proceeds to develop leukemia and celiac disease drugs.
MediWound sets terms for $92m Nasdaq IPO
The burns and wounds treatment developer's offering is at a value of $350-370 million.
Opko losses triple
CEO Phillip Frost: From an R&D perspective, all our programs are progressing.
D-Pharm doubles on good interim stroke study results
The Phase IIa trial interim results found the company's drug was safe for cerebral strokes.
Perrigo selling OTC drugs through Amazon
Perrigo: It is also a platform for obtaining good information about consumer behavior.
Teva launches bipolar, schizophrenia treatment
Adasuve is the first orally inhaled medicine for the acute treatment of agitation in schizophrenia and bipolar I disorder.
Perrigo acquires Aspen Global products for $51m
Perrigo bought value-brand OTC products sold in Australia and New Zealand.
Galmed updates $30m Nasdaq IPO prospectus
The liver disease drug developer will issue shares at a company value of $132 million.
Enzymotec shareholders raise $131m in offer to sell
Kibbutz Ma'anit's Galam reportedly sold shares for $46 million.
Compugen raises $63m, Magic $51m
The two companies held secondary offerings on Nasdaq on the basis of shelf prospectuses.
If Rose Fostanes played basketball
Reforms in regulations for foreign caregivers are welcome, but don't go far enough.
Private treatment kills public healthcare
If the German Committee validates private healthcare, it will be the last nail in public healthcare's coffin, argues Prof Dani Filc.
Reducing the number of polyps that colonoscopies miss
EndoChoice's Israel development center has devised an endoscope with a 330-degree arc.
Neopharm moves into orphan drugs
The company, better known for marketing others' products, has been quietly building up its innovative capacity, as VP Tal Fuhrer relates..
Merck Serono Israel incubator nurtures early stage projects
Merck Germany head of pharmaceuticals Dr. Stefan Oschmann says R&D is enjoying a renaissance at big pharma companies.